Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.15 USD | -3.38% | -8.08% | -38.43% |
May. 14 | Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading | MT |
May. 14 | Pliant Therapeutics Reports Positive Topline Data in Idiopathic Pulmonary Fibrosis Trial | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-38.43% | 673M | C- | ||
+45.82% | 765B | C+ | ||
+40.95% | 632B | B | ||
-6.16% | 354B | C+ | ||
+19.86% | 331B | B- | ||
+9.32% | 299B | C+ | ||
+18.45% | 248B | B+ | ||
-0.78% | 219B | A+ | ||
+11.88% | 216B | B- | ||
+5.90% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PLRX Stock
- Ratings Pliant Therapeutics, Inc.